Diabetic cardiomyopathy

Diabetic cardiomyopathy is a disorder of the heart muscle in people with diabetes mellitus, characterized by the ventricular dysfunction of the heart in the absence of coronary artery disease and hypertension. It is a significant complication of Type 1 and Type 2 diabetes, with its pathogenesis not entirely understood, though it is thought to result from a combination of metabolic disturbances linked to insulin resistance, microvascular disease, and cardiac autonomic neuropathy associated with diabetes.

Etiology and Pathophysiology

Diabetic cardiomyopathy is believed to result from a complex interplay of various factors including metabolic derangements such as hyperglycemia, insulin resistance, and elevated levels of free fatty acids. These factors lead to structural and functional changes in the myocardium, including myocardial fibrosis, left ventricular hypertrophy, and diastolic dysfunction. The disease progresses through stages, initially presenting as diastolic dysfunction and potentially advancing to systolic dysfunction and heart failure.

Hyperglycemia plays a pivotal role in the pathogenesis of diabetic cardiomyopathy, contributing to the accumulation of advanced glycation end products (AGEs) and the activation of the polyol pathway, which in turn lead to oxidative stress and endothelial dysfunction. Insulin resistance is another key factor, promoting lipid accumulation in cardiomyocytes and mitochondrial dysfunction.

Clinical Presentation

Patients with diabetic cardiomyopathy may initially be asymptomatic, but as the disease progresses, symptoms typical of heart failure may develop, including dyspnea, fatigue, and edema. The diagnosis is often made based on the clinical history, physical examination, and echocardiographic findings of left ventricular hypertrophy and impaired diastolic function, in the absence of other causes of heart failure.

Diagnosis

The diagnosis of diabetic cardiomyopathy involves a combination of clinical evaluation and diagnostic testing. Echocardiography is the primary imaging modality used to assess ventricular function and structure. Cardiac MRI may also be utilized for its superior ability to characterize myocardial tissue and detect fibrosis. Additionally, biomarkers such as NT-proBNP may be elevated in patients with diabetic cardiomyopathy and can aid in the diagnosis and monitoring of the disease.

Treatment

Management of diabetic cardiomyopathy focuses on tight glycemic control and the treatment of heart failure symptoms. Lifestyle modifications, including diet, exercise, and weight loss, are recommended to improve glycemic control and cardiovascular health. Pharmacological treatment may include the use of ACE inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, and diuretics to manage heart failure symptoms and prevent disease progression. Recent studies have also highlighted the potential benefits of newer antidiabetic drugs, such as SGLT2 inhibitors, in improving cardiac function and reducing heart failure hospitalizations in patients with diabetic cardiomyopathy.

Prognosis

The prognosis of diabetic cardiomyopathy is variable and depends on the stage of the disease at diagnosis, the effectiveness of glycemic control, and the management of heart failure symptoms. Early detection and aggressive management of diabetes and heart failure are crucial to improving outcomes.

See Also

• Heart failure
• Diabetes mellitus
• Cardiomyopathy

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian